Kornimate/medical-research-clean huggingface dataset:
donepezil trial for motor recovery in acute stroke

Conditions: Acute Stroke

Summary: aims: to establish: 1) whether motor deficits in acute stroke improve more in patients taking donepezil, relative to placebo, for 12 weeks; 2) whether brain functional mri changes as a result of donepezil after 12 weeks.

stroke is a major personal and social burden, being the commonest cause of severe adult disability. recovery has been shown in animal models to be dependent upon adequate levels of acetylcholine within the brain - which in stroke is likely to be deficient. this is because acetylcholine-producing nerve cells in the brain are often damaged by strokes. consequently, the investigators hypothesise that recovery may be improved by boosting acetylcholine levels in the brain - that can be readily achieved by treating with donepezil.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with acute stroke diagnosed on clinical and neuroimaging grounds who can enter the trial within the 1st week of stroke onset, and who have new motor dysfunction of an upper limb. motor impairment should be moderate - severe (ue-fm score ≤50 out of a total of 66). 2. age: above 18 years old. 3. patients able and willing to partake in motor tests, and to return for follow-up visit at 12 weeks. 4. able to understand english. exclusion criteria: 1. contraindications for donepezil: pregnancy (\* female patients \ 300 micromol/l; genitourinary tract or gastrointestinal tract obstruction; gastrointestinal tract hemorrhage; myasthenia gravis 2. other: functionally-significant cognitive impairment (i.e. dementia); significant receptive aphasia (i.e. such that cannot understand purpose or details of trial, and will be unable to cooperate with task instructions); significant physical infirmity as judged by treating physician (e.g. severe organ failure; terminal cancer). 3. contraindications for mri (this only pertains for the subset of patients entering the mri substudy, but is not a contra-indication to the main study providing a diagnosis of stroke is clear from ct): phobia, metal implants including pacemaker.

Keywords: cholinesterase inhibitor donepezil motor stroke
internet-based physical activity promotion and exercise prescription for people with multiple sclerosis (feasibility study)

Conditions: Multiple Sclerosis

Summary: this study evaluates the feasibility of a 12-week internet-based exercise and physical activity counseling intervention for people with multiple sclerosis (ms).

due to high inactivity rates in persons with multiple sclerosis (pwms) physical activity promotion for this target group is needed. the internet is an attractive and feasible medium for physical activity promotion, however interventions have to be adapted to the special needs of pwms. this study aims to evaluate the feasibility of a 12-week internet-based exercise and physical activity counseling intervention. 26 pwms will be enrolled in the study. all of them receive the intervention. focus groups and interviews will be conducted with participating pwms to determine acceptability of the intervention and to explore participants experiences. compliance with the intervention will be monitored. additionally, changes in objective physical activity, subjective physical activity, fatigue, walking ability and level of depression will be calculated.

Eligibility criteria:
inclusion criteria: * diagnosed multiple sclerosis (mcdonald criteria) * expanded disability status scale between 0 - 6.5 * neurologically stable (no exacerbation within 30 days prior to enrollment) * internet access (wifi) * basic knowledge on handling personal computer and the internet * owning a smartphone with the operating system android or ios and with access to google play store or apple app score * ability to read, write and comprehend as well as communicate electronically * not regularly physically active (more than 30 minutes twice a week with a moderate intensity (includes aerobic training, resistance training and other sports e.g. tennis; excludes physiotherapy, physical activity during work or household, grocery shopping, gardening, walking the dog etc.) exclusion criteria: * clinically relevant cardiovascular diseases * cortisone therapy in the last 30 days * cognitive impairment * severe impairment of hand function (ataxia or paresis impeding the use of a smartphone app or smartwatch) * severe internal, orthopaedic and metabolic diseases that restrict mobility

Keywords: multiple sclerosis e-health physical activity promotion exercise feasibility online internet based
mouth dissolving mosapride tables enhance post cesarean gut recovery

Conditions: Prevention of Postoperative Ileus

Summary: giving women one day before and immediately after cesarean section a mouthly dissolving mosapride tablets 2every every 8 hours for maximum of 5 days ,or getting recovered gastrointestinal functions and assess preoperative gastrointestinal functions

uncomplicated post cesarean women one day before and immediately after elective cesarean receive 2 mouthly dissolving mosapride tablets every 8 hours maximum for 5 days and clinical care giver follow the woman's gastrointestinal functions, including intraoperative and postoperative nausea vomiting, passing flatus, hearing intestinal sounds, passing stools, occurring of paralytic ileus, length of the hospital stay

Eligibility criteria:
inclusion criteria: * all women undergoing elective cesarean section exclusion criteria: * prior abdominal surgery, abdominal adhesion, chronic constipation, allergy to mosapride

Keywords: postoperative ileus mosapride mouth dissolving tablets intraoperative vomiting
physicians' awareness of ecg abnormalities linked to acute ischemic chest pain

Conditions: Physicians; Awareness; ECG Abnormalities; Acute Ischemic Chest Pain

Summary: this study aims to investigate physicians' awareness regarding patients presenting with potential acute ischemic chest pain. it focuses on various electrocardiogram (ecg) patterns requiring prompt catheter lab activation for reperfusion therapy alongside other ecg mimics that may lead to false catheter lab activations.

chest pain is the second most common complaint in adult emergency department (ed) patients in the united states. most visits result in a diagnosis of noncardiac chest pain and approximately half in nonspecific chest pain. roughly 6% are ultimately diagnosed with a life-threatening condition, which is overwhelmingly (\>90%) acute coronary syndrome (acs). the term acute coronary syndrome (acs) is applied to patients in whom there is a suspicion or confirmation of acute myocardial ischemia or infarction. st-elevation myocardial infarction (stemi), non-st-elevation mi (nstemi), and unstable angina are the three traditional types of acs.

Eligibility criteria:
inclusion criteria: * age from 25 to 65 years. * both sexes. * physicians who treat patients with possible acute chest pain. exclusion criteria: - participants who failed to complete the survey questions.
autologous stem cells derived from lipoaspirates for the non-surgical treatment of complex perianal fistula

Conditions: Anal Fistula

Summary: this comparative, multicentre, randomised clinical trial is designed with two parallel groups that will follow a treatment either with an autologous implant of ascs (adipose derived stem cells) and fibrin glue (tissue adhesive material) or with fibrin glue alone for the non-surgical treatment of complex perianal fistula.

comparative, multicentre, randomised clinical trial, designed with two parallel groups that will follow a treatment either with an autologous implant of ascs (adipose derived stem cells) and fibrin glue (tissue adhesive material) or with fibrin glue alone for the non-surgical treatment of complex perianal fistula. the closure/healing of the fistula will be evaluated periodically, and it will be considered completely closed if there is no suppuration from the external orifice and re-epithelialisation can be observed at 8 weeks after the administration of the randomised therapy.

Eligibility criteria:
inclusion criteria: * patients of both sexes older than 18 years of age. * patients with a complex perianal fistula pathology which we define as the subjects that fulfil some of the following conditions: * no palpation of the fistula tract beneath the perianal skin. * a tract that is parallel to the rectum on exploration with a stylet. * associated faecal incontinence. * risk factors of anal incontinence. * at least one previous operation for a fistulous disorder. * suprasphincteric trajectories * rectovaginal fistula * prior diagnosis of crohn's disease. * patients from whom written informed consent has been obtained for them to participate in the study prior to performing any procedure described in the study. * patients that have already been subjected to a colonoscopy within a period of up to 6 months prior to the study. exclusion criteria: * patients that are extremely thin who should not be subjected to liposuction. * known allergy to local anaesthetics or to bovine proteins * history of neoplasia in the past 5 years. * patients with a diagnosis of active tuberculosis at the moment of inclusion. * patients with prior positive markers for any of the following pathogens: hepatitis b and c, hiv-1 or hiv-2. * any other medical condition that in the judgement of the investigator could interfere with their optimal participation in the study or produce a significant risk to the patient. * patients that have participated in another study in the 30 days prior to this one or that have planned to participate simultaneously in another study. * patients that have not given their informed consent to participate in this study. * psychiatric disorder or other factors that in the judgement of the investigator could complicate the participation of the patient in the study. * breast feeding, gestation or intention to become pregnant up to 6 months after finalising their participation in the study, or that are not using adequate methods of contraception during the same period.

Keywords: ascs (adult stem cells derived from adipose tissue) fistula cell therapy complex perianal fistula
safety and efficacy study of a new treatment for symptoms of urinary incontinence

Conditions: Urinary Incontinence

Summary: the purpose of this study is to determine if a new drug treatment is effective for the treatment of symptoms of urinary incontinence.


Eligibility criteria:
inclusion criteria: * women who have moderate to severe urge, stress or mixed urinary incontinence exclusion criteria: * medical history of migraines, neurologic problems, swallowing disorder, stroke or severe depression. * medical history of heart failure, peripheral edema or moderate to severe asthma or chronic obstructive pulmonary disease (copd) * certain restricted medications * any other condition that would interfere with the safety of the subject

Keywords: urinary incontinence stress incontinence urge incontinence mixed incontinence
internet-administered smoking cessation treatment for overweight and obese smokers

Conditions: Smoking Cessation; Overweight; Obesity

Summary: this project will be a randomized clinical trial testing the efficacy of an internet-administered smoking cessation treatment for overweight and obese smokers. research on internet-administered behavioral treatments for smoking cessation has found that compared to control treatments (e.g., self-help materials), cessation rates in internet-administered treatments are significantly higher. research testing the applicability of these treatments to overweight and obese individuals has not yet been conducted. given that a substantial portion of smokers are also overweight and at elevated cardiovascular risk, there is a need for directed treatment efforts for this group. the current trial proposes to be the first to test the effectiveness of internet-administered smoking cessation treatment for overweight and obese (bmi≥25) smokers. adult participants will be randomized to receive 12 weeks of internet-administered treatment consisting of either: a) standard smoking cessation treatment with general health education, or b) standard smoking cessation treatment with cognitive behavioral therapy (cbt) for weight concerns. participants in both conditions will receive open-label treatment with the 21 mg transdermal nicotine patch.


Eligibility criteria:
inclusion criteria: * smoking 10 or more cigarettes per day * regular access to the internet * bmi\>=25 exclusion criteria: * type i diabetes or type ii diabetes requiring medication * alcohol or drug dependence within the past year * females with current pregnancy or breastfeeding or intention to become pregnant within the next 12 months * uncontrolled hypertension * severe chronic obstructive pulmonary disease * use of an investigational drug within 30 days or current participation in another clinical trial * current use of tobacco products other than cigarettes or use of marijuana * use of nicotine replacement therapy, clonidine, varenicline, bupropion, or nortriptyline within the month prior to enrollment * use of a medication that might affect weight or appetite * history of allergic reactions to adhesives.

Keywords: smoking cessation overweight obesity internet treatment
islet after kidney transplant for type 1 diabetes

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of this study is to determine if prolonged administration of the anti tnf (tumor necrosis factor)-alpha agent etanercept is associated with enhanced graft survival in patients undergoing islet after kidney transplantation.


Eligibility criteria:
inclusion criteria: * patients with type 1 diabetes mellitus, who have a stable functioning renal transplant, are taking the appropriate maintenance immunosuppression and have no severe health problems that preclude them receiving an islet transplant will be considered for inclusion. exclusion criteria: * have a history of or findings suggestive of unstable diabetic complications (e.g. active eye disease) * active infections (clinically or by laboratory testing) * history of current malignancy or suspicion of malignancy until properly investigated and excluded * liver or biliary abnormalities * unstable cardiovascular disease * findings to suggest immunological sensitization or those women who have the potential to get pregnant and are not using a sufficient method of contraception

Keywords: islet transplantation type 1 diabetes mellitus kidney transplantation
the effect of α-lipoic acid treatment in patient with cardiac autonomic neuropathy

Conditions: Type 2 Diabetes; Cardiac Autonomic Neuropathy

Summary: the purpose of this study is to see if it is safe and effective to give alpha lipoic acid in people with cardiac autonomic neuropathy(can). cardiac autonomic neuropathy(can) affects the nerves that control heart rate and blood flow to the heart in people with diabetes. can may cause problems with the rhythm of the heartbeat or decrease blood flow to the heart.

study type : interventional study design : allocation: randomized control: no treatment endpoint classification: safety/efficacy study intervention model: parallel assignment masking: open label primary purpose: treatment primary outcome measures : heart rate variability(hrv) index secondary outcome measures : autonomic nerve system(ans) function 5 test, euroqol 5-dimension questionnaire(eq-5d)

Eligibility criteria:
inclusion criteria : * established cardiac autonomic neuropathy in type 2 diabetes. * aged 20 years to 80 years * capable of giving informed consent exclusion criteria : * history of other significant disease such as the nerve system (parkinson's disease, epilepsy, multiple sclerosis), hepatic disease, hypothyroid, etc other medical condition or treatment likely to affect the autonomic nerve system * hba1c \> 11% * not controlled hypertension (sbp≥160mmhg, dbp≥100mmhg) * diagnosed ketoacidosis within 4 weeks * unstable cardiac disease (unstable angina or myocardial infarction ) * pregnancy * involvement in other clinical trial in last 4 weeks * known or suspected sensitivity to trial products

Keywords: cardiac autonomic neuropathy
effects of milk powder intervention on blood glucose control and fluctuation in middle-aged and elderly people with pre-diabetes

Conditions: Pre-diabetes

Summary: this study aims to conduct a 8-week intervention involving one formula milk powder for middle-aged and elderly individuals with pre-diabetes, assessing its impact on blood glucose control and fluctuations in comparison to interventions using regular milk powder.


Eligibility criteria:
inclusion criteria: 1. age between 40 and 75 years, regardless of gender. 2. impaired fasting glucose (5.6 mmol/l ≤ fpg \< 6.9 mmol/l) or glycated hemoglobin (hba1c) between 5.7-6.4% (39-47 mmol/mol). 3. resided in guangzhou for the past six months and no plans to relocate or travel outside the city in the next month. 4. signed informed consent form and voluntarily agreed to participate in the project. exclusion criteria: 1. patients with a confirmed diagnosis of diabetes who are currently taking glucose-lowering medications (e.g., insulin, glp-1 receptor agonists, or sglt2 inhibitors). 2. individuals with lactose intolerance or dairy product intolerance. 3. pregnant, planning to become pregnant within the next three months, or currently breastfeeding. 4. weight change \> 5% in the past three months or plans to lose weight or change dietary habits. 5. alcohol consumption \> 40g/day. 6. individuals with communication barriers, cognitive impairments, or other conditions that may prevent them from completing the study procedures. 7. severe diseases that may affect participation in the study, including but not limited to endocrine disorders, severe cardiovascular or cerebrovascular diseases, cancer, metabolic diseases, etc. 8. participation in or current involvement in other clinical trials within the past three months. 9. no use of antibiotic medications within the past three months.
a roll-over study to provide continued treatment with lyophilized pegaspargase (s95014) in pediatric patients with acute lymphoblastic leukemia (all)

Conditions: Acute Lymphoblastic Leukemia

Summary: the purpose of this study is to provide treatment with lyophilized s95014 in pediatric patients with all who completed the cl2-95014-002 study during the induction phase and who are clinically benefitting from s95014 without major toxicity.


Eligibility criteria:
inclusion criteria: * patient who completed the cl2-95014-002 study * patient currently receiving clinical benefit from previous treatment with s95014 as per investigator's judgment * signed informed consent and assent, when appropriate * highly effective contraception method non-inclusion criteria: * unlikely to cooperate in the study * pregnant and lactating women * participant already enrolled in the study (informed consent signed) * prior surgery or bone marrow transplant related to the studied disease * history of sensitivity to polyethylene glycol (peg) or peg-based drugs * psychiatric illness/social situation that would limit compliance with study requirements * group "e" and "t-hr" patients according to all-mb 2015 protocol classification * major safety issue due to previous s95014 administration (e.g. non recovery of safety parameters, serious hypersensitivity, serious pancreatitis, serious haemorrhage, serious thromboembolic event) * significant laboratory abnormality or uncontrolled intercurrent illness (e.g. life-threatening acute tumor lysis syndrome, symptomatic congestive heart failure, cardiac arrhythmia, severe or uncontrolled active acute infection) likely to jeopardize the patients' safety or to interfere with the conduct of the study, in the investigator's opinion

Keywords: acute lymphoblastic leukemia phase ii oncology / haematology continued treatment pegaspargase lyophilized pegaspargase roll-over study / extension study
exercise intervention study for pancreatic cancer patients

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to compare the effects of two specific exercise interventions and one standard care control arm on physical functioning.the investigators expect that supervised training is most beneficial to the patients. however, they also expect some benefit for patients in the home-based training.

the randomized-controlled balanced-parallel-group trial included 65 adult pancreatic cancer patients (stage i-iv) from the university surgery clinic in heidelberg. the study compared two specific exercise interventions and one standard care control arm. the intervention programs were (1) a 6-month supervised moderate-to-high-intensity, progressive resistance training, and (2) a 6-month home-based exercise training. thus, the two interventions differed primarily by the intensity and mode-of-administration of the intervention. both interventions started at the earliest 8 weeks after surgery to allow for wound healing until maximum 12 months after the surgery. the supervised progressive training started with only moderate-intensity training during the first 4 weeks. only patients without comorbidities that preclude participation in the intervention arms (e.g. severe pain, heart insufficiency, reduced standing or walking ability) were eligible. the primary objective is to compare the effects of the different interventions on physical functioning, measured as change from baseline to 6 months. additional endpoints are overall quality of life, fatigue, endurance, and strength performance, adherence to the interventions, discontinuation of adjuvant therapy, body weight and composition, disease progression, overall and progression-free survival. all outcomes has been assessed every 3 months for a minimum follow-up period of 12 months.

Eligibility criteria:
inclusion criteria: * pancreatic cancer patients (stage i-iv) * patients ≥ 18 years of age * resection performed at the university clinic of heidelberg * sufficient german language skills * signed informed consent exclusion criteria: • presence of comorbidities that preclude participation in the intervention arms (e.g. severe pain, heart insufficiency, reduced standing or walking ability)

Keywords: pancreatic cancer exercise training quality of life physical functioning